Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily

BACKGROUND: In a phase 3 study, the authors assessed the effects of dasatinib at doses of 140 mg once daily and 70 mg twice daily in patients who had either chronic myeloid leukemia (CML) in advanced phases or Philadelphia chromosome-positive acute lymphoblastic leukemia and were resistant or intole...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Saglio, Giuseppe, Hochhaus, Andreas, Goh, Yeow Tee, Masszi, Tamas, Pasquini, Ricardo, Maloisel, Frederic, Erben, Philipp, Cortes, Jorge, Paquette, Ronald, Bradley-Garelik, M. Brigid, Zhu, Chao, Dombret, Herve
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4993589/
https://ncbi.nlm.nih.gov/pubmed/20564086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25123
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge